MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

MDT

87.92

-0.94%↓

A

115.46

-1.22%↓

VEEV

157.06

-5.63%↓

HQY

83.88

+2.36%↑

TLRY

6.71

-0.3%↓

Search

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

175.85 0.23

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

169.44

Massimo

175.9

Metriche Chiave

By Trading Economics

Entrata

-332M

-277M

Vendite

-11M

994M

Margine di Profitto

-27.816

Dipendenti

18,300

EBITDA

730K

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+17.6% upside

Dividendi

By Dow Jones

Utili prossimi

6 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

359M

8.3B

Apertura precedente

175.62

Chiusura precedente

175.85

Notizie sul Sentiment di mercato

By Acuity

16%

84%

36 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10 apr 2026, 00:00 UTC

Principali Notizie su Eventi

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9 apr 2026, 23:44 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9 apr 2026, 23:34 UTC

Discorsi di Mercato

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9 apr 2026, 23:14 UTC

Discorsi di Mercato

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9 apr 2026, 23:14 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

9 apr 2026, 23:07 UTC

Discorsi di Mercato

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9 apr 2026, 22:54 UTC

Discorsi di Mercato

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9 apr 2026, 22:31 UTC

Principali Notizie su Eventi

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9 apr 2026, 22:31 UTC

Principali Notizie su Eventi

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9 apr 2026, 20:57 UTC

Principali Notizie su Eventi

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9 apr 2026, 20:55 UTC

Utili

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9 apr 2026, 20:55 UTC

Utili

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9 apr 2026, 20:55 UTC

Utili

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9 apr 2026, 20:50 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

9 apr 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

9 apr 2026, 20:40 UTC

Acquisizioni, Fusioni, Takeovers

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9 apr 2026, 20:39 UTC

Acquisizioni, Fusioni, Takeovers

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9 apr 2026, 20:39 UTC

Acquisizioni, Fusioni, Takeovers

Rowan Digital Infrastructure Announces Strategic Recapitalization

9 apr 2026, 20:25 UTC

Acquisizioni, Fusioni, Takeovers

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9 apr 2026, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

9 apr 2026, 19:30 UTC

Principali Notizie su Eventi

How Digital Currencies Have Helped Iran -- WSJ

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

17.6% in crescita

Previsioni per 12 mesi

Media 205.89 USD  17.6%

Alto 265 USD

Basso 175 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

8

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

36 / 348 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat